Headline News

 

Takeda Opens First Platinum Energy Building in Singapore

Posted on March 30, 2023

EMA granting market authorization for KaulivTM, a recombinant human teriparatide biosimilar to treat osteoporosis

Posted on March 30, 2023

Collaboration with BioNTech and OncoC4 to Co-Develop Novel Checkpoint Antibody in Multiple Solid Tumor Indications

Posted on March 27, 2023

Roche’s Evrysdi reinforce long-term efficacy and safety profile in most severely affected people with types 2 and 3 spinal muscular atrophy

Posted on March 27, 2023

Takeda Approval to Manufacture and Market Entyvio® Subcutaneous Injection for the Maintenance Treatment of Moderate to Severe Ulcerative Colitis

Posted on March 27, 2023

Risankizumab Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis

Posted on March 27, 2023

Upadacitinib to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

Posted on March 27, 2023

AstraZenecas Calquence granted first regulatory approval for adults with mantle cell lymphoma

Posted on March 27, 2023

Eplontersen showed sustained benefit in Phase III trial

Posted on March 27, 2023

Dupixent® potential to become the first biologic to treat COPD by showing major reduction in exacerbations

Posted on March 27, 2023

Dupixent approved as first and only targeted medicine for children as young as six months old with severe atopic dermatitis

Posted on March 27, 2023

Merck Update On Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab

Posted on March 20, 2023

BioNTech and OncoC4 to Co-Develop and Commercialize Novel Antibody in Multiple Solid Tumor Indications

Posted on March 20, 2023

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial on Schizophrenia

Posted on March 20, 2023

China National Medical accepts regulatory submission for Nucala in severe eosinophilic asthma

Posted on March 20, 2023